SelectQuote, Inc. Reports First Quarter of Fiscal Year 2026 Results

SelectQuote, Inc. (NYSE: SLQT) reported consolidated revenue for the first quarter of fiscal year 2026 of $328.8 million compared to consolidated revenue for the first quarter of fiscal year 2025 of $292.3 million. Consolidated net loss for the first quarter of fiscal year 2026 was $30.5 million compared to consolidated net loss for the first quarter of fiscal year 2025 of $44.5 million. Finally, consolidated Adjusted EBITDA* for the first quarter of fiscal year 2026 was $(32.1) million compared to consolidated Adjusted EBITDA* for the first quarter of fiscal year 2025 of $(1.7) million.

Tim Danker, SelectQuote Chief Executive Officer, remarked “The strength of our integrated healthcare model was exhibited again in our fiscal first quarter. Early work to prepare for new eligibility parameters in this year’s Medicare Advantage special election period was evident in our Senior business. We successfully reallocated resources and agents for the expected decline in volume and, as a result, performed well in the quarter and more importantly positioned our Senior business for another strong season. We firmly maintain our view that SelectQuote’s Medicare Advantage business has durable competitive advantage and flexibility to drive strong results in a range of environments. While the past three years have presented different challenges and opportunities, SelectQuote has excelled and validated our visibility and confidence in the generation of return and cash flow in our Senior distribution business.”

Mr. Danker added, “Our Healthcare Services business also continues to perform well, serving over 100,000 SelectRx members with convenient drug delivery that drives improved health outcomes. Our value-added prescription drug delivery and patient adherence pharmacy offers real, differentiated value to both the patient and the insurance payor. When our data and service approach provides better care, patients win, and do so at more efficient cost to the overall healthcare system. We continue to see SelectQuote as a healthcare services ecosystem that can create system-wide value in a range of use cases. In this quarter, SelectQuote generated a revenue to customer acquisition cost (CAC) ratio of 6.4x, which is an all-time high and nearly 40% higher than it was a year ago. While profitability is our ultimate north star, we view this metric as a strong indicator on how we are helping our customers with more and more, each and every year.”

Mr. Danker concluded, “At this time, we are not changing our fiscal 2026 financial outlook of $1.65 to $1.75 billion in revenue and $120 to $150 million in Adjusted EBITDA*. In Healthcare Services, a temporary reimbursement rate headwind in our SelectRx business impacted this quarter and we expect will drive adjusted EBITDA around breakeven for the segment in the fiscal second quarter. SelectQuote and our PBM partners are committed to the significant value provided to patients of SelectRx, and we expect Healthcare Services to exit fiscal 2026 at an Adjusted EBITDA run rate in the $40 to $50 million range.”

* See “Non-GAAP Financial Measures” below.

Segment Results

We currently have three reportable segments: 1) Senior, 2) Healthcare Services and 3) Life. The performance measures of the segments include total revenue and adjusted EBITDA. Costs of commissions and other services revenue, cost of goods sold-pharmacy revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount. Adjusted EBITDA is our segment profit measure to evaluate the operating performance of our business. We define Adjusted EBITDA as net income (loss) before income tax expense (benefit) plus interest expense, depreciation and amortization, changes in fair value of warrant liabilities, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. Adjusted EBITDA margin is calculated as adjusted EBITDA divided by revenue.

Senior

Financial Results

The following table provides the financial results for the Senior segment for the periods presented:

		Three Months Ended September 30,
(in thousands)		2025				2024				% Change
Revenue		$	58,996			$	92,908			(37	)%
Adjusted EBITDA			(21,036	)			7,724			(372	)%
Adjusted EBITDA Margin			(36	)%			8	%

Operating Metrics

Submitted Policies

Submitted policies are counted when an individual completes an application with our licensed agent and provides authorization to the agent to submit the application to the insurance carrier partner. The applicant may have additional actions to take before the application will be reviewed by the insurance carrier.

The following table shows the number of submitted policies for the periods presented:

		Three Months Ended September 30,
		2025		2024		% Change
Medicare Advantage		70,240		102,281		(31	)%
All other (1)		17,174		16,256		6	%
Total		87,414		118,537		(26	)%
(1) Represents the submitted policies for Medicare supplement, dental, vision and hearing, prescription drug plan and other.

Approved Policies

Approved policies represents the number of submitted policies that were approved by our insurance carrier partners for the identified product during the indicated period. Not all approved policies will go in force.

The following table shows the number of approved policies for the periods presented:

		Three Months Ended September 30,
		2025		2024		% Change
Medicare Advantage		62,510		91,680		(32	)%
All other (1)		13,876		12,979		7	%
Total		76,386		104,659		(27	)%
(1) Represents the approved policies for Medicare supplement, dental, vision and hearing, prescription drug plan and other.

Lifetime Value of Commissions per Approved Policy

Lifetime value of commissions per approved policy represents commissions estimated to be collected over the estimated life of an approved policy based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints. The lifetime value of commissions per approved policy is equal to the sum of the commission revenue due upon the initial sale of a policy, and when applicable, an estimate of future renewal commissions.

The following table shows the lifetime value of commissions per approved policy for the periods presented:

		Three Months Ended September 30,
(dollars per policy):		2025			2024			% Change
Medicare Advantage		$	769		$	812		(5	)%
All other(1)			133			165		(19	)%
(1) Represents the weighted average LTV per approved policy.

Healthcare Services

Financial Results

The following table provides the financial results for the Healthcare Services segment for the periods presented:

		Three Months Ended September 30,
(in thousands)		2025				2024				% Change
Revenue		$	221,351			$	155,739			42	%
Adjusted EBITDA			7,212				4,878			48	%
Adjusted EBITDA Margin			3	%			3	%

Operating Metrics

Members

The total number of SelectRx members represents the amount of active customers to which an order has been shipped and the prescriptions per day represents the total average prescriptions shipped per business day. These two metrics are the primary drivers of revenue for Healthcare Services.

The following table shows the total number of SelectRx members as of the periods presented:

		September 30, 2025		September 30, 2024
Total SelectRx Members		106,914		86,521

The total number of SelectRx members increased by 24% as of September 30, 2025, compared to September 30, 2024, due to our strategy to grow SelectRx membership.

The following table shows the average prescriptions shipped per day for the periods presented:

		Three Months Ended September 30,
		2025		2024
Prescriptions Per Day		31,378		24,998

Combined Senior and Healthcare Services - Consumer Per Unit Economics

Combined Senior and Healthcare Services consumer per unit economics represents total MA and MS commissions; other product commissions; other revenues, including revenues from Healthcare Services; and operating expenses associated with Senior and Healthcare Services, each shown per number of approved MA and MS policies over a given time period. Management assesses the business on a per-unit basis to help ensure that the revenue opportunity associated with a successful policy sale is attractive relative to the marketing acquisition cost. Because not all acquired leads result in a successful policy sale, all per-policy metrics are based on approved policies, which is the measure that triggers revenue recognition.

The MA and MS commission per MA/MS policy represents the LTV for policies sold in the period. Other commission per MA/MS policy represents the LTV for other products sold in the period, including DVH prescription drug plan, and other products, which management views as additional commission revenue on our agents’ core function of MA/MS policy sales. Pharmacy revenue per MA/MS policy represents revenue from SelectRx, and other revenue per MA/MS policy represents revenue from Population Health, production bonuses, marketing development funds, lead generation revenue, and adjustments from the Company’s reassessment of its cohorts’ transaction prices. Total operating expenses per MA/MS policy represents all of the operating expenses within Senior and Healthcare Services. The revenue to customer acquisition cost (“CAC”) multiple represents total revenue as a multiple of total marketing acquisition cost, which represents the direct costs of acquiring leads. These costs are included in marketing and advertising expense within the total operating expenses per MA/MS policy.

The following table shows combined Senior and Healthcare Services consumer per unit economics for the periods presented. Based on the seasonality of Senior and the fluctuations between quarters, we believe that the most relevant view of per unit economics is on a rolling 12-month basis. All per MA/MS policy metrics below are based on the sum of approved MA/MS policies, as both products have similar commission profiles.

		Twelve Months Ended September 30,
(dollars per approved policy):		2025				2024
MA and MS approved policies			565,529				621,040
MA and MS commission per MA / MS policy		$	884			$	919
Other commission per MA/MS policy			13				12
Pharmacy revenue per MA/MS policy			1,405				842
Other revenue per MA/MS policy			129				152
Total revenue per MA / MS policy			2,431				1,925
Total operating expenses per MA / MS policy			(2,147	)			(1,626	)
Adjusted EBITDA per MA/MS policy		$	284			$	299
Adjusted EBITDA Margin per MA/MS policy			12	%			16	%
Revenue / CAC multiple		6.4X				4.6X

Total revenue per MA/MS policy increased 26% for the twelve months ended September 30, 2025, compared to the twelve months ended September 30, 2024, primarily due to the increase in pharmacy revenue. Total operating expenses per MA/MS policy increased 32% for the twelve months ended September 30, 2025, compared to the twelve months ended September 30, 2024, driven by an increase in cost of goods sold-pharmacy revenue for Healthcare Services due to the growth of the business.

Life

Financial Results

The following table provides the financial results for the Life segment for the periods presented:

		Three Months Ended September 30,
(in thousands)		2025				2024				% Change
Revenue		$	46,647			$	39,290			19	%
Adjusted EBITDA			5,570				5,960			(7	)%
Adjusted EBITDA Margin			12	%			15	%

Operating Metrics

Life premium represents the total premium value for all policies that were approved by the relevant insurance carrier partner and for which the policy document was sent to the policyholder and payment information was received by the relevant insurance carrier partner during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Life segment.

The following table shows term and final expense premiums for the periods presented:

		Three Months Ended September 30,
(in thousands)		2025			2024			% Change
Term Premiums		$	19,443		$	15,218		28	%
Final Expense Premiums			29,429			24,473		20	%
Total		$	48,872		$	39,691		23	%

Earnings Conference Call

SelectQuote, Inc. will host a conference call with the investment community on November 6, 2025 beginning at 8:30 a.m. ET. To register for this conference call, please use this link: https://registrations.events/direct/Q4I4247512. After registering, a confirmation will be sent via email, including dial-in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call we suggest registering at least 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website https://ir.selectquote.com/investor-home/default.aspx.

Non-GAAP Financial Measures

This release includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this release Adjusted EBITDA, which, when presented on a consolidated basis, is a non-GAAP financial measure. This non-GAAP financial measure is not based on any standardized methodology prescribed by GAAP and is not necessarily comparable to any similarly titled measure presented by other companies. We define Adjusted EBITDA as net income (loss) plus interest expense, income taxes, depreciation and amortization, changes in fair value of warrant liabilities, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure is net income (loss). We monitor and have presented in this release Adjusted EBITDA because it is a key measure used by our management and Board of Directors to understand and evaluate our operating performance, establish budgets, and develop operational goals for managing our business. In particular, we believe that excluding the impact of these expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance.

A reconciliation of the differences between Adjusted EBITDA and its most directly comparable GAAP measure, net income (loss), is presented below on page 14. The Company is unable to provide a quantitative reconciliation of forward-looking Adjusted EBITDA to its most directly comparable GAAP measure without unreasonable effort because it is not possible to predict certain information included in the calculation of such GAAP measure, including the fair value of outstanding warrants to purchase shares of the Company's common stock. The unavailable information could have a significant impact on the Company’s GAAP financial results.

Forward Looking Statements

This release contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as “may,” “should,” “could,” “predict,” “potential,” “believe,” “will likely result,” “expect,” “continue,” “will,” “anticipate,” “seek,” “estimate,” “intend,” “plan,” “projection,” “would” and “outlook,” or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.

There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the U.S. health insurance system; our dependence on revenue from carriers in our senior segment and downturns in the senior health as well as life, automotive and home insurance industries; our ability to develop new offerings and penetrate new vertical markets; risks from third-party products; failure to enroll individuals during the Medicare annual enrollment period; our ability to attract, integrate and retain qualified personnel; our dependence on lead providers and ability to compete for leads; failure to obtain and/or convert sales leads to actual sales of insurance policies; access to data from consumers and insurance carriers; accuracy of information provided from and to consumers during the insurance shopping process; cost-effective advertisement through internet search engines; ability to contact consumers and market products by telephone; global economic conditions, including inflation and tariffs; disruption to operations as a result of future acquisitions; significant estimates and assumptions in the preparation of our financial statements; impairment of goodwill; existing or potential litigation and other legal proceedings or inquiries, including the Department of Justice action alleging violations of the federal False Claims Act; our existing and future indebtedness; our ability to maintain compliance with our debt covenants; access to additional capital; failure to protect our intellectual property and our brand; fluctuations in our financial results caused by seasonality; accuracy and timeliness of commissions reports from insurance carriers; timing of insurance carriers’ approval and payment practices; factors that impact our estimate of the constrained lifetime value of commissions per policyholder; changes in accounting rules, tax legislation and other legislation; disruptions or failures of our technological infrastructure and platform; failure to maintain relationships with third-party service providers; cybersecurity breaches or other attacks involving our systems or those of our insurance carrier partners or third-party service providers; our ability to protect consumer information and other data; failure to market and sell Medicare plans effectively or in compliance with laws; and other factors related to our pharmacy business, including manufacturing or supply chain disruptions, access to and demand for prescription drugs, contractual reimbursement rates, and regulatory changes or other industry developments that may affect our pharmacy operations. For a further discussion of these and other risk factors that could impact our future results and performance, see the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2025 and subsequent periodic reports filed by us with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

About SelectQuote:

Founded in 1985, SelectQuote (NYSE: SLQT) pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies, allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote’s success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads. Today, the Company operates an ecosystem offering high touchpoints for consumers across insurance, pharmacy, and virtual care.

With an ecosystem offering engagement points for consumers across insurance, Medicare, pharmacy, and value-based care, the company now has three core business lines: SelectQuote Senior, SelectQuote Healthcare Services, and SelectQuote Life. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a Patient-Centered Pharmacy Home (PCPH) accredited pharmacy, SelectPatient Management, a provider of chronic care management services, and Healthcare Select which proactively connects consumers with a wide breadth of healthcare services supporting their needs.

SELECTQUOTE, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands)
		September 30, 2025				June 30, 2025
ASSETS
CURRENT ASSETS:
Cash, cash equivalents, and restricted cash		$	14,461			$	35,733
Accounts receivable, net of allowances of $11.6 million and $11.8 million, respectively			104,485				151,388
Commissions receivable-current			193,395				132,077
Other current assets			19,622				21,844
Total current assets			331,963				341,042
COMMISSIONS RECEIVABLE—Net			786,434				818,751
PROPERTY AND EQUIPMENT—Net			14,377				14,577
SOFTWARE—Net			15,782				15,060
OPERATING LEASE RIGHT-OF-USE ASSETS			23,615				24,635
INTANGIBLE ASSETS—Net			1,689				1,973
GOODWILL			29,438				29,438
OTHER ASSETS			3,678				3,880
TOTAL ASSETS		$	1,206,976			$	1,249,356
LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable		$	34,567			$	59,205
Accrued expenses			50,001				13,856
Accrued compensation and benefits			49,816				58,788
Operating lease liabilities—current			4,886				4,820
Current portion of long-term debt			68,337				68,523
Contract liabilities			1,971				698
Other current liabilities			6,152				7,020
Total current liabilities			215,730				212,910
LONG-TERM DEBT, NET—less current portion			324,812				316,589
DEFERRED INCOME TAXES			28,703				37,872
OPERATING LEASE LIABILITIES			24,812				25,982
OTHER LIABILITIES			65,993				80,485
Total liabilities			660,050				673,838
COMMITMENTS AND CONTINGENCIES
PREFERRED STOCK:
Senior Non-Convertible Preferred Stock, $0.01 par value, 350,000 shares issued and outstanding as of September 30, 2025 and June 30, 2025, respectively, current liquidation preference of $380.4 million and $367.1 million as of September 30, 2025 and June 30, 2025.			241,856				224,374
SHAREHOLDERS’ EQUITY:
Common stock, $0.01 par value			1,759				1,728
Additional paid-in capital			555,959				571,605
Accumulated deficit			(252,648	)			(222,189	)
Total shareholders’ equity			305,070				351,144
TOTAL LIABILITIES, PREFERRED STOCK, AND SHAREHOLDERS’ EQUITY		$	1,206,976			$	1,249,356

SELECTQUOTE, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)
(In thousands)
		Three Months Ended September 30,
		2025				2024
REVENUE:
Commissions and other services		$	110,267			$	139,380
Pharmacy			218,544				152,883
Total revenue			328,811				292,263
OPERATING COSTS AND EXPENSES:
Cost of commissions and other services revenue			69,101				65,733
Cost of goods sold—pharmacy revenue			192,779				129,524
Marketing and advertising			61,947				63,764
Selling, general, and administrative			35,819				36,145
Technical development			9,911				9,074
Total operating costs and expenses			369,557				304,240
LOSS FROM OPERATIONS			(40,746	)			(11,977	)
INTEREST EXPENSE, NET			(11,808	)			(23,031	)
CHANGE IN FAIR VALUE OF WARRANTS			15,036				—
OTHER EXPENSE, NET			(145	)			(12	)
LOSS BEFORE INCOME TAX EXPENSE (BENEFIT)			(37,663	)			(35,020	)
INCOME TAX EXPENSE (BENEFIT)			(7,204	)			9,526
NET LOSS		$	(30,459	)		$	(44,546	)
Senior Non-Convertible Preferred Stock accumulated dividends and accretion			(17,482	)			—
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS		$	(47,941	)		$	(44,546	)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS PER SHARE:
Basic		$	(0.26	)		$	(0.26	)
Diluted		$	(0.26	)		$	(0.26	)
WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS:
Basic			185,816				170,431
Diluted			185,816				170,431
OTHER COMPREHENSIVE LOSS, NET OF TAX:
Unrealized loss, net of related tax benefit of $0.0 million and $0.0 million			—				(39	)
Amount reclassified into earnings, net of related tax benefit of $0.0 million and $1.0 million			—				(2,746	)
OTHER COMPREHENSIVE LOSS			—				(2,785	)
COMPREHENSIVE LOSS		$	(30,459	)		$	(47,331	)

SELECTQUOTE, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
		Three Months Ended September 30,
		2025				2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		$	(30,459	)		$	(44,546	)
Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities:
Depreciation and amortization			4,300				5,599
Loss on disposal of property, equipment, and software			—				68
Share-based compensation expense			4,327				3,846
Deferred income taxes			(9,168	)			9,526
Amortization of debt issuance costs and debt discount			1,184				1,064
Accrued interest payable in kind			—				5,289
Change in fair value of warrants			(15,036	)			—
Non-cash lease expense			1,021				903
Changes in operating assets and liabilities:
Accounts receivable, net			46,902				50,501
Commissions receivable			(29,001	)			(38,466	)
Other assets			2,371				(3,516	)
Accounts payable and accrued expenses			11,395				12,761
Operating lease liabilities			(1,105	)			(1,127	)
Other liabilities			(8,354	)			(18,512	)
Net cash used in operating activities			(21,623	)			(16,610	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment			(1,058	)			(442	)
Purchases of software and capitalized software development costs			(2,926	)			(2,132	)
Net cash used in investing activities			(3,984	)			(2,574	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving credit facility			80,000				—
Payments on revolving credit facility			(65,000	)			—
Payments on Term Loans			(3,573	)			(8,471	)
Payments on ABS Notes			(4,543	)			—
Payments on other debt			(112	)			(30	)
Proceeds from common stock options exercised and employee stock purchase plan			—				38
Payments of tax withholdings related to net share settlement of equity awards			(2,460	)			(3,915	)
Payments of debt issuance costs			(72	)			(684	)
Net cash provided by (used in) financing activities			4,240				(13,062	)
NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH			(21,367	)			(32,246	)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH—Beginning of period			37,066				42,690
CASH, CASH EQUIVALENTS AND RESTRICTED CASH—End of period		$	15,699			$	10,444

SELECTQUOTE, INC. AND SUBSIDIARIES
Adjusted EBITDA to Loss before income tax expense (benefit) Reconciliation by Segment
(Unaudited)
		Three Months Ended September 30, 2025
(in thousands)		Senior				Healthcare Services				Life				Total
Total revenue from reportable segments		$	58,996			$	221,351			$	46,647			$	326,994
Less:
Cost of commissions and other services revenue			(41,897	)			(6,301	)			(17,979	)
Cost of goods sold - pharmacy revenue			—				(191,398	)			—
Marketing expense			(37,630	)			(2,389	)			(22,760	)
Technical development			—				(438	)			—
Selling, general, and administrative			(505	)			(13,613	)			(338	)
Adjusted Segment EBITDA		$	(21,036	)		$	7,212			$	5,570			$	(8,254	)
Reconciliation of total segment Adjusted EBITDA
All other Adjusted EBITDA															1,888
Corporate															(25,713	)
Share-based compensation expense															(4,327	)
Transaction costs															(185	)
Depreciation and amortization															(4,300	)
Change in fair value of warrants															15,036
Interest expense, net															(11,808	)
Loss before income tax expense (benefit)														$	(37,663	)

SELECTQUOTE, INC. AND SUBSIDIARIES
Adjusted EBITDA to Loss before income tax expense (benefit) Reconciliation by Segment
(Unaudited)
		Three Months Ended September 30, 2024
(in thousands)		Senior				Healthcare Services				Life				Total
Total revenue from reportable segments		$	92,908			$	155,739			$	39,290			$	287,937
Less:
Cost of commissions and other services revenue			(41,127	)			(5,879	)			(14,572	)
Cost of goods sold - pharmacy revenue			—				(128,366	)			—
Marketing expense			(43,378	)			(2,247	)			(18,496	)
Technical development			—				(608	)			—
Selling, general, and administrative			(679	)			(13,761	)			(262	)
Adjusted Segment EBITDA		$	7,724			$	4,878			$	5,960			$	18,562
Reconciliation of total segment Adjusted EBITDA
All other Adjusted EBITDA															3,797
Corporate															(24,042	)
Share-based compensation expense															(3,846	)
Transaction costs															(826	)
Depreciation and amortization															(5,599	)
Loss on disposal of property, equipment, and software, net															(35	)
Interest expense, net															(23,031	)
Loss before income tax expense (benefit)														$	(35,020	)

RECONCILIATION OF NON-GAAP MEASURE
SELECTQUOTE, INC. AND SUBSIDIARIES
Reconciliation of Net loss to Adjusted EBITDA
(Unaudited)
		Three Months Ended September 30,
(in thousands)		2025				2024
Net loss		$	(30,459	)		$	(44,546	)
Share-based compensation expense			4,327				3,846
Transaction costs			185				826
Depreciation and amortization			4,300				5,599
Loss on disposal of property, equipment, and software, net			—				35
Change in fair value of warrants			(15,036	)			—
Interest expense, net			11,808				23,031
Income tax expense (benefit)			(7,204	)			9,526
Adjusted EBITDA		$	(32,079	)		$	(1,683	)

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20251106390529/en/

The SelectQuote Stock at the time of publication of the news with a raise of +5,59 % to 1,890EUR on Tradegate stock exchange (05. November 2025, 22:26 Uhr).